GILD · News · 20260804N
Guidance / Outlook
GILEAD SCIENCES, INC. · 2026-08-04 · Importance 82 · Surprise 100 · In source text
Gilead raised its 2026 base-business and product-sales outlook after second-quarter strength in HIV treatment and prevention products, Trodelvy, and Livdelzi. HIV growth expectations were increased, while HIV prevention sales exceeded $1 billion in the quarter. Management also lowered its full-year outlook for Veklury after an 81% year-over-year sales decline in the second quarter. The company projected a 2026 adjusted loss of approximately $0.30 to $0.65 per share, primarily reflecting acquisition-related research and development charges.
Key facts
- Gilead provided a full-year 2026 adjusted loss forecast ranging from $0.30 to $0.65 per share. source
- Gilead raised its full-year base business sales outlook for 2026 following Q2 results. source
- Gilead increased the lower end of its full-year product sales guidance after Q2 2026. source
- Gilead raised its expected HIV growth rate and increased its full-year base business sales outlook on the Q2 2026 earnings call. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | probable | — | Gilead provided a full-year 2026 adjusted loss forecast ranging from $0.30 to $0.65 per share. |
| revenue | positive | probable | — | Gilead increased the lower end of its full-year product sales guidance after Q2 2026. |